672 related articles for article (PubMed ID: 32285726)
21. Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.
Murali R; Selenica P; Brown DN; Cheetham RK; Chandramohan R; Claros NL; Bouvier N; Cheng DT; Soslow RA; Weigelt B; McCluggage WG
Histopathology; 2019 Mar; 74(4):638-650. PubMed ID: 30565721
[TBL] [Abstract][Full Text] [Related]
22. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
23. Stage-specific embryonic antigen 4 expression in epithelial ovarian carcinoma.
Ye F; Li Y; Hu Y; Zhou C; Hu Y; Chen H
Int J Gynecol Cancer; 2010 Aug; 20(6):958-64. PubMed ID: 20683402
[TBL] [Abstract][Full Text] [Related]
24. Decreased Eph receptor‑A1 expression is related to grade in ovarian serous carcinoma.
Jin Y; Zou Y; Wan L; Lu M; Liu Y; Huang G; Wang J; Xi Q
Mol Med Rep; 2018 Apr; 17(4):5409-5415. PubMed ID: 29393455
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of miRNA-21, -103, -129, -150 in serous ovarian cancer.
Wilczyński M; Żytko E; Danielska J; Szymańska B; Dzieniecka M; Nowak M; Malinowski J; Owczarek D; Wilczyński JR
Arch Gynecol Obstet; 2018 Mar; 297(3):741-748. PubMed ID: 29335784
[TBL] [Abstract][Full Text] [Related]
26. Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma.
Davidson B; Bock AJ; Holth A; Nymoen DA
Cytopathology; 2020 Nov; 31(6):572-578. PubMed ID: 32741023
[TBL] [Abstract][Full Text] [Related]
27. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.
Eckert MA; Coscia F; Chryplewicz A; Chang JW; Hernandez KM; Pan S; Tienda SM; Nahotko DA; Li G; Blaženović I; Lastra RR; Curtis M; Yamada SD; Perets R; McGregor SM; Andrade J; Fiehn O; Moellering RE; Mann M; Lengyel E
Nature; 2019 May; 569(7758):723-728. PubMed ID: 31043742
[TBL] [Abstract][Full Text] [Related]
28. Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization.
Wang Y; Zeng J; Wu W; Xie S; Yu H; Li G; Zhu T; Li F; Lu J; Wang GY; Xie X; Zhang J
Breast Cancer Res; 2019 May; 21(1):64. PubMed ID: 31101119
[TBL] [Abstract][Full Text] [Related]
29. Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
Qiu C; Wang Y; Wang X; Zhang Q; Li Y; Xu Y; Jin C; Bu H; Zheng W; Yang X; Lu N; Kong B
Int J Oncol; 2018 Jun; 52(6):2041-2050. PubMed ID: 29620196
[TBL] [Abstract][Full Text] [Related]
30. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
[TBL] [Abstract][Full Text] [Related]
31. Mammary serine protease inhibitor and CD138 immunohistochemical expression in ovarian serous and clear cell carcinomas.
Hasby EA
Tumour Biol; 2016 Apr; 37(4):4889-900. PubMed ID: 26526579
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
33. Accumulation of Nicotinamide N-Methyltransferase (NNMT) in Cancer-associated Fibroblasts: A Potential Prognostic and Predictive Biomarker for Gastric Carcinoma.
Zhang L; Song M; Zhang F; Yuan H; Chang W; Yu G; Niu Y
J Histochem Cytochem; 2021 Mar; 69(3):165-176. PubMed ID: 33283625
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression.
Nilforoushan N; Moatamed NA
Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
36. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
37. Long Non-coding RNA
Yim GW; Kim HJ; Kim LK; Kim SW; Kim S; Nam EJ; Kim YT
Cancer Res Treat; 2017 Jul; 49(3):656-668. PubMed ID: 27737536
[TBL] [Abstract][Full Text] [Related]
38. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
39. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
[TBL] [Abstract][Full Text] [Related]
40. Outcome in serous ovarian cancer is not associated with LATS expression.
Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
